Deciphering Tumor Heterogeneity and Optimizing Precision Therapeutic Strategies in Refractory Cancers

Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal adenocarcinoma, and metastatic urothelial carcinoma, are driven by extensive intratumoral heterogeneity and the adaptive capacity of the tumor microenvironment. These properties confer formidable barriers to treatment, fueling recurrence and resistance through rare subclonal populations that escape conventional therapies. Bulk tumor analyses often overlook this complexity, masking dynamic cellular ecosystems and underestimating the impact of metabolic and immune interactions within the tumor. While single-cell resolution techniques have illuminated the diversity of tumor and stromal cells, critical challenges persist in translating these data into clinically effective interventions. Notably, current gaps include a limited understanding of how specific subpopulations orchestrate immune escape, metabolic rewiring, and drug resistance, as well as the absence of tailored therapeutic strategies that can selectively dismantle resilient tumor cell networks.

This Research Topic aims to redefine precision oncology for intractable cancers by leveraging high-resolution single-cell profiling to uncover actionable vulnerabilities within complex tumor ecosystems. The central goal is to move from descriptive molecular atlases towards functional insights that enable the development of targeted therapies, focusing on dissecting the specific molecular and cellular drivers of resistance. We seek to integrate computational biology, pharmacological innovation, and experimental approaches to pinpoint unique subclonal targets and develop novel agents, particularly those derived from natural products and traditional medicine, which may offer multifaceted actions suitable for overcoming multidimensional therapeutic barriers. By focusing on both mechanistic exploration and therapeutic application, this initiative endeavors to bridge the translational gap between single-cell discoveries and patient-preferred, precision treatment regimens.

The scope of this Research Topic encompasses studies focused on refractory tumors that employ single-cell technologies to unravel tumor heterogeneity and guide innovative therapies. Submissions are expected to concentrate on the integration of multi-omics data, computational modeling, and pharmacological evaluation, with clear connections to therapeutic resistance and immune evasion. We welcome articles including, but not limited to, the following themes:

o High-resolution mapping of cellular subpopulations and evolutionary trajectories in refractory cancers
o Identification and functional validation of resistance-driving molecular signatures
o Mechanistic studies on immune modulation and metabolic adaptation within the tumor microenvironment
o Development and characterization of novel therapeutic agents, including natural products, that target specific subclones
o Computational and high-throughput screening strategies to discover and prioritize new drug targets
o Approaches for integrating molecular subtyping into precision treatment decision-making

We welcome submissions of Original Research, Reviews, and Methods, as well as computational or experimental articles, that advance the field of precision management in refractory tumors.